Novartis AG (NVS) Tests Copy of Amgen (AMGN)'s Enbrel in Late-Stage Trial
6/24/2013 7:48:29 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Sandoz, the generics unit of Novartis, has launched a late-stage trial with its biosimilar version of Amgen's Enbrel, consolidating its leading position in developing cheaper copies of complex biotech drugs. With the start of the major study of its version of Enbrel, or etanercept, Sandoz now has seven Phase III clinical trials across five biosimilar molecules - more than any other company in the industry. Sandoz said on Monday the new trial aimed to confirm the biosimilarity of its product versus Enbrel in patients with moderate to severe chronic plaque-type psoriasis. Results will be used to support U.S. and European regulatory filings.
Help employers find you! Check out all the jobs and post your resume.
comments powered by